US5019761049
© Globe Newswire
15.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
News Preview
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
News Preview
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – – Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
29.10.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
News Preview
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.10.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
News Preview
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
News Preview
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
News Preview
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
News Preview
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
News Preview
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
News Preview
Webcast to be held August 28, 2025, 11:00am ET
EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Lead...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
News Preview
EMERYVILLE, Calif., May 28, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conferen...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
News Preview
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026
Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug A...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.03.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis
Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Applicat...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
News Preview
EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma C...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
KYTX
LISTED
NASDAQ
Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Stat...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
KYTX
LISTED
NASDAQ
KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
News Preview
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX), if they purchased the C...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
KYTX
LISTED
NASDAQ
Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). Th...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
News Preview
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth
EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company fo...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization
First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis an...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
KYTX
LISTED
NASDAQ
Kirby McInerney LLP Urges Investors in Kyverna Therapeutics, Inc. to Inquire About Their Rights in Class Action Lawsuit
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ:KYTX) securities between February 4, 2024, to December 9, 2024 (“the Class Period”). Inve...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
News Preview
EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
KYTX
LISTED
NASDAQ
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
KYTX
LISTED
NASDAQ
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kyverna Therapeutics, Inc. (KYTX)
News Preview
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration St...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
KYTX
LISTED
NASDAQ
KYTX Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). Th...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
KYTX
LISTED
NASDAQ
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kyverna Therapeutics, Inc. (KYTX)
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming February 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the C...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
KYTX
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Statement issued i...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
KYTX
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 202...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
KYTX
LISTED
NASDAQ
KYTX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna’s registration statement issued in connection with Kyverna’s initial public offering (the “IPO”) held on February 8, 2024, have until February 7, 2025 to seek appointment as lead...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2024
KYTX
LISTED
NASDAQ
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
14.12.2024
KYTX
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 2024 initial public offering (the “IPO”...
Themefolio
Profiler
Peergroup
© PR Newswire
13.12.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
News Preview
Key Leadership Appointments Bring New Skills and Capabilities to Organization
EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Busi...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
KYTX
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) investors concerning the Company’s possible violations of federal securities laws.
On or about February 8, 2024, Kyverna conducted its initial public offering (“IPO”), selling 14.5 million shares of common...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
KYTX
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your K...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
KYTX
LISTED
NASDAQ
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna’s registration statement issued in connection with Kyverna’s initial public offering (“IPO”) held on February 8, 2024, have until February 7, 2025 to seek appoint...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
KYTX
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On or about February 8, 2024, Kyverna cond...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
KYTX
LISTED
NASDAQ
KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX), if they purchased the Compa...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
KYTX
LISTED
NASDAQ
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company’s initial public offering conducted on February 7, 2024 (the “IPO”). Kyverna is a “clinical-stage biopharmaceutical compan...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
KYTX
LISTED
NASDAQ
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) for violations of the federal securities laws.
Investors who purchased the Company's securities pursuant and/or traceable to the Company’s offering...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
KYTX
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) and reminds investors of the February 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
KYTX
LISTED
NASDAQ
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities Class Action lawsuit in the United States District Court for the Northern District of California against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX), certain directors and officers, a...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
News Preview
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose
KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed
EMERYVILLE, Calif., Nov. 14, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
News Preview
Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy
Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
News Preview
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy
EMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clin...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
News Preview
Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101's initial efficacy and safety profile and broad potential in B cell-driven neuroinflammatory diseases
Key biomarkers indicate potential for KYV-101 to durably modify neuroinflammatory diseases with...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Leadership Update
News Preview
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
– Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeuti...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
News Preview
EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events:...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
News Preview
Actively recruiting clinical trials in neurology and rheumatology with KYV-101No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person SyndromeReceived FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
News Preview
The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program
The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage on more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101
EMERYVILLE, Cali...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
